Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1107054

Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.


Vrdoljak, Eduard; Sekerija, Mario; Plestina, Stjepko; Belac Lovasic, Ingrid; Katalinic Jankovic, Vera; Garattini, Livio; Bobinac, Ana; Voncina, Luka
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. // The European journal of health economics, 22 (2021), nije jos dodijeljen broj, 16 doi:10.1007/s10198-020-01262-0 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1107054 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.

Autori
Vrdoljak, Eduard ; Sekerija, Mario ; Plestina, Stjepko ; Belac Lovasic, Ingrid ; Katalinic Jankovic, Vera ; Garattini, Livio ; Bobinac, Ana ; Voncina, Luka

Izvornik
The European journal of health economics (1618-7598) 22 (2021); Nije jos dodijeljen broj, 16

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Economic evaluation, National plan against cancer, Cost per LYG, ICER
(Economic evaluation National plan against cancer Cost per LYG ICER)

Sažetak
This cost-effectiveness study analyses the expected impacts of activities proposed by the Croatian National Plan Against Cancer (NPAC) on cancer incidence and survival rates, as related to their respective costs. We evaluated the impact of the NPAC on two main outcomes, namely, reduced incidence and the improved survival of cancer patients, expressed as life years gained (LYGs), which enabled the calculation of incremental cost-effectiveness ratios (ICERs) in the form of cost per LYG. In the analysis of costs, we considered both the direct costs of NPAC activities as well as the wider indirect societal costs of cancer, thus permitting the calculation of the ICER both from the narrower national health insurer’s perspective (accounting only for the direct costs) and the wider societal perspective (accounting both for the direct and indirect costs). We estimated that on average, for all patients benefiting from the implementation of the NPAC in Croatia, an additional LYG would be yielded at the additional cost of €1.021 (societal perspective). The NPAC can, for some sites, even be considered a dominant intervention due to the negative cost/LYG ratio, meaning that it generates additional LYGs while at the same time, reducing total societal costs. Taking a narrower health insurer’s perspective (i.e., accounting only for the direct costs), the NPAC produces an additional LYG at an additional cost of €1.408. Both cost per LYG estimates can be considered cost-effective investment options.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita, Ekonomija, Interdisciplinarne društvene znanosti



POVEZANOST RADA


Projekti:
UIP-2019-04-3721 - Vrijednost u zdravstvu: emprijska istraživanja i aplikacija (VIHEEA) (Bobinac, Ana, HRZZ - 2019-04) ( POIROT)

Ustanove:
Hrvatski zavod za javno zdravstvo,
Medicinski fakultet, Rijeka,
Ekonomski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Medicinski fakultet, Split,
Klinički bolnički centar Rijeka,
Fakultet zdravstvenih studija u Rijeci

Citiraj ovu publikaciju

Vrdoljak, Eduard; Sekerija, Mario; Plestina, Stjepko; Belac Lovasic, Ingrid; Katalinic Jankovic, Vera; Garattini, Livio; Bobinac, Ana; Voncina, Luka
Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer. // The European journal of health economics, 22 (2021), nije jos dodijeljen broj, 16 doi:10.1007/s10198-020-01262-0 (međunarodna recenzija, članak, znanstveni)
Vrdoljak, E., Sekerija, M., Plestina, S., Belac Lovasic, I., Katalinic Jankovic, V., Garattini, L., Bobinac, A. & Voncina, L. (2021) Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.. The European journal of health economics, 22, nije jos dodijeljen broj, 16 doi:10.1007/s10198-020-01262-0.
@article{article, year = {2021}, pages = {16}, DOI = {10.1007/s10198-020-01262-0}, chapter = {nije jos dodijeljen broj}, keywords = {Economic evaluation, National plan against cancer, Cost per LYG, ICER}, journal = {The European journal of health economics}, doi = {10.1007/s10198-020-01262-0}, volume = {22}, issn = {1618-7598}, title = {Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.}, keyword = {Economic evaluation, National plan against cancer, Cost per LYG, ICER}, chapternumber = {nije jos dodijeljen broj} }
@article{article, year = {2021}, pages = {16}, DOI = {10.1007/s10198-020-01262-0}, chapter = {nije jos dodijeljen broj}, keywords = {Economic evaluation National plan against cancer Cost per LYG ICER}, journal = {The European journal of health economics}, doi = {10.1007/s10198-020-01262-0}, volume = {22}, issn = {1618-7598}, title = {Is it too expensive to fight cancer? Analysis of incremental costs and benefits of the Croatian National Plan Against Cancer.}, keyword = {Economic evaluation National plan against cancer Cost per LYG ICER}, chapternumber = {nije jos dodijeljen broj} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Social Science Citation Index (SSCI)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font